Dual targeting of lymphocyte homing and retention through α4β7 and αEβ7 inhibition in inflammatory bowel disease
Bingbing Dai, Jason A. Hackney, Ryan Ichikawa, Allen Nguyen, Justin Elstrott, Luz D. Orozco, Kai-Hui Sun, Zora Modrušan, Alvin Gogineni, Alexis Scherl, John Gubatan, Aida Habtezion, Monika Deswal, Ma Somsouk, William A. Faubion, Akiko Chai, Zaineb Sharafali, Azra Hassanali, Young S. Oh, Swati Tole, Jacqueline McBride, Mary Keir, Tangsheng Yi
Abstract
T cells. Etrolizumab-treated patients with CD display a treatment-specific reduction in inflammatory and cytotoxic intraepithelial lymphocytes (IEL) genes. Concurrent blockade of α4β7 and αEβ7 promotes reduction of cytotoxic IELs and inflammatory T cells in the gut mucosa through a stepwise inhibition of intestinal tissue entry and retention.
Topics & Concepts
Intraepithelial lymphocyteCytotoxic T cellBlockadeCD8ImmunologyInflammatory bowel diseaseLymphatic systemLymphocyte homing receptorHoming (biology)BiologyT cellInflammationIntestinal mucosaCancer researchIntegrinLymphocyteCellMedicineImmune systemDiseasePathologyReceptorCell adhesionIn vitroInternal medicineBiochemistryEcologyGeneticsInflammatory Bowel DiseaseImmunodeficiency and Autoimmune DisordersT-cell and B-cell Immunology